CSIMarket Company Name, Ticker, Industry, else..
 
Sonnet Biotherapeutics Holdings Inc   (NASDAQ: SONN)
 
Price: $1.2750 $-1.83 -58.871%
Day's High: $3.38 Week Perf: -69.35 %
Day's Low: $ 1.26 30 Day Perf: -74.6 %
Volume (M): 8,293,366 52 Wk High: $ 7.90
Volume (M$): $ 10,574 52 Wk Avg: $4.64
Open: $3.13 52 Wk Low: $1.26



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 4
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 0

Business Description


Sonnet Biotherapeutics Holdings Inc is a biotechnology company that specializes in developing innovative targeted immunotherapies for cancer treatments. The company focuses on utilizing its proprietary platform technology, called Immunopeptidomics, to create personalized medicines for patients with various types of cancer. Sonnet's approach involves identifying and targeting specific peptides expressed on cancer cells, leading to more effective and personalized treatments that can potentially enhance patient outcomes. The company's goal is to revolutionize cancer therapy by providing patients with highly personalized and targeted treatments that harness the power of the immune system to fight cancer.


   Company Address: 100 Overlook Center Princeton 8540 NJ
   Company Phone Number: 375-2227   Stock Exchange / Ticker: NASDAQ SONN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.7%    
CTMX        2.13% 
MDGL        5.48% 
PFE        1.75% 
RYTM   -4.76%    
SUPN   -2%    
• View Complete Report
   



Clinical Study

Sonnets SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resi...

Published Sun, Apr 6 2025 2:11 AM UTC

Unveiling Innovative Treatments: Sonnet BioTherapeutics Promising Trials for Ovarian Cancer and Chemotherapy-Induced Peripheral NeuropathyIn the ever-evolving landscape of biopharmaceuticals, companies continuously strive to bring forth innovative treatments that target unmet medical needs. One such company is Sonnet BioTherapeutics Holdings, Inc. renowned for its cutting-...
Management Announcement

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Published Tue, Apr 1 2025 11:30 AM UTC

A Legacy of Innovation: Sonnet BioTherapeutics Mourns Founder and CEO Pankaj Mohan, Ph.D. while Steering Forward Amid ChallengesPRINCETON, N.J. April 1, 2025 – In a profound moment of tragedy, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the unexpected passing of its esteemed founder and Chief Executive Officer, Pankaj Mohan, Ph.D. The news comes as a sig...
Clinical Study

Sonnet BioTherapeutics Advances Immunotherapy Pipeline with New Patent Allowance and ASCO 2024 Presentation

Published Wed, Mar 19 2025 12:57 PM UTC

Advancements in Immunotherapy: Sonnet BioTherapeutics Promising Developments and Patent Innovations Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company at the forefront of developing innovative targeted biologic therapies, has recently marked significant milestones in its evolving research portfolio. The company announced receipt of a Notice of...
Contract

In the ongoing battle against one of the deadliest forms of cancer, pancreatic cancer remains a formidable ...

Published Mon, Aug 19 2024 12:45 PM UTC

Innovative Approaches to Pancreatic Cancer Treatment: Sonnet BioTherapeutics SON-1210 Clinical CollaborationIn the ongoing battle against one of the deadliest forms of cancer, pancreatic cancer remains a formidable challenge due to its late diagnosis and poor prognosis. Research teams and pharmaceutical companies are tirelessly seeking innovative solutions to improve treat...
Clinical Study

Positive Phase 1b Data Supports Advancement of SON-080 for Chemotherapy-Induced Peripheral Neuropathy

Published Wed, Jul 24 2024 12:30 PM UTC

In a recent announcement, Sonnet BioTherapeutics Holdings, Inc. revealed encouraging data from the Phase 1b portion of its Phase 1b/2a clinical trial evaluating SON-080 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). This milestone supports the further development of SON-080 into Phase 2, highlighting its potential as a targeted immunotherapeutic drug...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.20
Price to Sales (Expected) -
Price to Book 0.48
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.25
Working Capital Ratio 3.5
Leverage Ratio (MRQ) 0.38
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.79 $
Revenues (TTM) 0.25 $
Cash Flow (TTM) 3.24 $
Cash 1.25 $
Book Value 2.64 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,779,054
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.